CXCR4 and ulcerative colitis: Utilizing ulcerative colitis and apical periodontitis as inflammatory disease models, it is found that CXCR4/Cur‐CMVs are obviously aggregated within inflammatory areas after intravenous administration, which results in significant amelioration of ulcerative colitis and apical periodontitis.